Kornimate/medical-research-clean huggingface dataset:
impact of high-level oxygen therapy on the reconditioning of type i hypoxemic respiratory insufficiency patients in intensive care

Conditions: Hypoxemic Respiratory Failure

Summary: high-throughput oxygen therapy is known as an alternative to non-invasive ventilation, with a benefit in terms of survival in non-hypercapnic respiratory failure patients. the use of high-throughput oxygen therapy is well studied in stable chronic obstructive pulmonary disease (copd) patients and has as known effects the decrease of transcutaneous co2 and respiratory rate, and the increase in the inspiratory/expiratory time report, in the tidal volume and in the forced expiratory volume per second. in the event of an exacerbation, high-flow oxygen therapy has shown to be beneficial in terms of increased mean airway pressure, tidal volume with a decrease in hypercapnia, and respiratory rate. the net effect on the co2 pressure is linked to the co2 clearance of the dead anatomical space by the high throughput. the effect can be compared with the one of non invasive ventilation in a stable copd patient. oxygen therapy, even in patients with non-hypoxic copd at rest, has benefits in terms of performance and improvement of quality of life. high-throughput oxygen therapy has also shown a benefit in copd patients in revalidation units, in terms of exercise performance and oxygenation. however, the reconditioning of critical patients in acute situations, by means of nasal goggles, has never been studied.


Eligibility criteria:
inclusion criteria: * acute respiratory insufficiency type i, oxygen partial pressure (pao2) \<60 mmhg under oxygen without hypercapnia. * invasive arterial pressure measure exclusion criteria: * hemodynamic instability * patient under continuous high throughput oxygen therapy * left cardiac insufficiency * arteritis of the lower limbs * neuromuscular pathology * osteo-articular limitations * hemoglobin inferior to 8g/dl
effect of a synbiotic "probiotical®/bactecal® " in asthma

Conditions: Asthma

Summary: it is a randomized double blind placebo control study. one hundred severe asthmatic patients will receive "probiotical ®/bactecal®" each day during 3 months and will be evaluated before and 1-3-6 months after in order to assess the impact of the synbiotic on the lung function, the exhaled nitric oxide value, the inflammatory blood and sputum profiles, the bronchial reactivity, the microvascular health and the quality of life and asthma control. the hypothesis is that, as these patients are not optimally controlled, the synbiotic could have an impact by decreasing the inflammation state at local and systemic level and then improve the quality of life and the asthma control. indeed, synbiotic have been shown to possess beneficial effects on the immune system.

thirty percent of asthmatic patients are not well controlled even with an optimal treatment. there is then a need for new therapeutics allowing a better asthma control. synbiotic (association of probiotics and prebiotics) have been shown to have anti-inflammatory properties as well as immunomodulatory activities. moreover, synbiotic appeared to be very well tolerated and safe. one hundred severe asthmatic patients (acq\> 1.5 and beclomethasone \> 200 µg per day) will receive "probiotical ®/bactecal®" (3 pills a day, content: lactobacillus, bifidobacterium et streptococcus thermophilus, 18 billion of bacteria per pill) or a placebo during 3 months. they will be evaluated before and 1-3-6 months after the first administration and different tests will be realized: * lung function tests (spirometry, lung volumes, diffusing capacity) * exhaled nitric oxide value (feno, linked to airway eosinophilia) * blood tests: leucocyte count, c reactive protein, fibrinogen. plasma and serum will be kept for inflammatory mediators measurements. * sputum induction: leucocyte count and mediators measurements using the sputum supernatant and sputum cells. * bronchial reactivity (bronchial challenge test) * microvascular health: to assess the glycocalyx state, see: http://glycocheck.com/ for details. * questionnaires: asthma control test (act), asthma control questionnaire (acq), asthma quality of life questionnaire (aqlq ).

Eligibility criteria:
inclusion criteria: * severe asthma (acq \>1.5 and treatment = minimum 200 µg beclomethasone) and stable treatment for at least 3 months. exclusion criteria: * treatment not stable * exacerbation state * infection

Keywords: severe asthma synbiotic immunomodulation sputum
customer support response study

Conditions: Type 2 Diabetes

Summary: the primary objective of the custom study is to respond to customer support issues (outside of the us) and to assess the impact of a particular treatment or perturbation relative to an initial control measurement. sequential subject measurements will be analyzed to determine if a given action or condition induces a score shift, an inflation of measurement variance or elevated outlier rates.

the scout ds device is not yet approved by the fda for sale in the united states, but currently is being marketed in canada and other countries. customers who are using the device have contacted the sponsor with questions about testing conditions which might affect the reproducibility of measurements. the objective is to obtain information to allow the sponsor to address these issues. the concerns fall into three broad categories: • factors affecting the interface between the skin and the test sensor these would include the effects of skin care products applied to the forearm, subject activity that changes perfusion to the skin and subject movement during the test procedure. * general operating conditions issues such as ambient temperature, lighting, and height of the table on which the scout ds device rests have been questioned as possible factors influencing accuracy. * rare subject disorders included here would be subject skin abnormalities or physiologic changes which occur so infrequently that they were not well represented in previous data sets. examples of such rare conditions would include scleroderma, capillary angiomata, and raynaud phenomenon.

Eligibility criteria:
inclusion criteria: * males and/or females greater than or equal to 18 years of age exclusion criteria: * have received investigational treatments in the past 14 days * have psychosocial issues that interfere with an ability to follow study procedures * are known to be pregnant * have scars, tattoos, rashes or other disruption/discoloration on the left volar forearm. * have been treated on the past month with oral steroid therapy or topical steroids applied to the left forearm. inhaled steroid therapy is not a basis for exclusion * are receiving medications that fluoresce (a list of excluded medications is located in appendix h) * are known to have, or at risk for, photosensitivity reactions (e.g., sensitive to ultraviolet light, or taking medication known to cause photosensitivity)

Keywords: screening for type 2 diabetes
evaluation of a natural experiment to improve statewide depression care in minnesota (mn)

Conditions: Major Depression

Summary: the study will evaluate a unique natural experiment that aims to transform the primary care of patients with depression. the experiment's aim is to cause statewide implementation of an evidence-based care model for depression by changing the reimbursement system and by using an established regional collaborative (the institute for clinical systems improvement) to both facilitate the model's widespread use and certify that medical groups have implemented it. study hypotheses include the following: 1. newly treated depressed patients in medical groups that have implemented the new reimbursement and facilitation will report receiving higher rates of best care processes than such patients in these medical groups before implementation. 2. rates of best care practices reported to be received by newly treated depressed patients two years after each medical group implements changes will be maintained at least at the rate reported by patients one year post implementation. 3. newly treated depressed patients in medical groups that have participated in the new reimbursement and facilitation will have greater improvement in depression symptoms and work productivity and lower healthcare costs than such patients in groups before participation. 4. medical group measures of priority for improving depression care, capability to manage change, and practice systems will be predictive of more patient-reported best care processes, both at one point in time and in change over time.

the study will use a multiple baseline across settings with staggered implementation to test the effects of changed reimbursement and facilitated organizational change on the use and sustainability of evidenced-based care processes for patients with depression. the study will also test the effect of the care process changes on changes in depression symptoms, healthcare costs, and work productivity.

Eligibility criteria:
inclusion criteria: * major depression * patient health questionaire (phq-9) \> 9 * primary care management of depression exclusion criteria: * comorbid psychiatric conditions
effects of two sugar substituted chewing gums on caries and gingivitis variables

Conditions: Dental Plaque; Saliva Altered; Gingivitis

Summary: the purpose of this study is to determine the effect of three times a day mastication, during a follow-up period of 4 weeks, of two sugar-substituted chewing gums on various factors associated with dental caries and gingivitis.

the purpose of this paper is to compare the effect of daily consumption of two sugar-free chewing gum, one with recaldent and one with xylitol, added to traditional hygiene (brushing, fluoridated toothpaste and dental floss), in clinical features such as the accumulation of plaque and gingival inflammation, microbiological characteristics of saliva as the counts of cariogenic microorganisms and facultative anaerobes, and some physicochemical properties of saliva such as ph and concentrations of calcium and inorganic phosphate. to this there was a general call among dental students at the university of antioquia and those who expressed their intention to participate voluntarily with informed consent, were examined clinically and randomly assigned to one of the study groups (recaldent or xylitol) or the control group. after a month of baseline examination and the daily use of the same instruments of oral hygiene and chewing of 6 pellets of each chewing gum (in the case of study groups), all variables are re-examined.

Eligibility criteria:
inclusion criteria: * systemically healthy * dental student exclusion criteria: * less than 26 teeth in mouth * use of orthodontic appliances * use of antibiotics the last 3 months

Keywords: prevention & control xylitol casein phosphopeptide amorphous calcium phosphate complex streptococcus mutans saliva dental plaque gingivitis
electrical stimulation of abdominal muscles for bowel management in people with spinal cord injury

Conditions: Neurogenic Bowel

Summary: a well-managed bowel program is an essential part of daily life for many people with a sci. nevertheless, constipation is frequently reported (42-95%). constipation embraces a spectrum of harms including both physical \& psychological distress. initial exploratory studies suggest abdominal fes may be useful for decreasing overall bowel management time, decreasing colonic transit time and reducing discomfort. the current study will seek to reproduce previous findings in a 12 week study, using overall bowel management time as a benchmark for establishing proof of principle. the study will include 36 people with a spinal cord injury aged 18 and over with an above t12 injury, a complete or incomplete lesion in a medically stable condition, one year or more after injury. participants will be randomised into two groups. one group will receive abdominal electrical stimulation and the other group low dose abdominal electrical stimulation. participants will be asked to keep a bowel diary and complete questionnaires examining quality of life and bowel management.


Eligibility criteria:
* inclusion criteria: * people with a diagnosis of spinal cord injury * age =\>18 years of age * injury level at or above t12 * complete or incomplete spinal cord lesion * medically stable condition * reflex bowel * =\>1 year post spinal cord injury * exclusion criteria: * a history of organic bowel obstruction * frequent opioid use, * intrathecal baclofen or percutaneous endoscopic gastrostomy * inflammatory bowel disease * recent abdominal hernia * recent gastrointestinal or abdominal surgery * lower motor neuron lesions, * suspected strictures or fistulae along the gastrointestinal tract * physiologic gastrointestinal obstruction. * other causes of constipation such as hypothyroidism, hypercalcaemia * constipation predominant irritable bowel syndrome prior to diagnosis of sci * involvement in other research trial interventions likely to impact current trial * poorly controlled epilepsy, * cardiac pacemaker in situ * other implanted electrical devices * pregnancy or pregnancy planned * cancerous tissue in the abdominal region * any major skin disorders affecting the abdominal area) * severe autonomic dysreflexia (tested at initial assessment).
transplant navigator dissemination

Conditions: Kidney Transplant; Renal Failure Chronic Requiring Hemodialysis

Summary: primary aim a. to disseminate and determine the impact of streamlined navigation on wait listing and number of transplants. the navigator will provide tailored information and assistance to help dialysis patients complete the tasks required at each step in the transplant process. in the control group, dialysis patients will continue to get usual care from their nephrologists and dialysis facility personnel. hypothesis: compared to control patients, intervention patients will be significantly more likely to be wait listed or receive a kidney transplant.


Eligibility criteria:
inclusion criteria: * between the ages of 18-70 * receiving in center hemodialysis exclusion criteria: * less than 18 years of age * older than 70 years of age

Keywords: navigators kidney transplant hemodialysis
clinical endpoint bioequivalence study of adapalene gel 0.1%

Conditions: Acne Vulgaris

Summary: to evaluate the therapeutic equivalence of topical adapalene gel, 0.1 % and differin®(adapalene) gel, 0.1 % in the treatment of acne vulgaris and to demonstrate the superiority of the efficacy of the test and reference products over the placebo.

bio-equivalence study with a clinical endpoint in the treatment of acne vulgaris comparing adapalene cream, 0.1% test product versus the reference listed drug (rld) and placebo (vehicle) control, each administered as one application once a day in the evening for 12 weeks

Eligibility criteria:
inclusion criteria: 1. male or nonpregnant, nonlactating female aged ≥ 12 and ≤ 40 years with a clinical diagnosis of acne vulgaris 2. on the face, ≥ 25 non-inflammatory lesions (i.e., open and closed comedones) and ≥ 20 inflammatory lesions (i.e., papules and pustules) and ≤ 2 nodulocystic lesions (i.e., nodules and cysts) 3. investigator's global assessment (iga) of acne severity grade 2, 3, or 4 4. willing to refrain from use of all other topical acne medications or antibiotics during the 12-week treatment period 5. if female of childbearing potential, willing to use an acceptable form of birth control during the study exclusion criteria: 1. pregnant, breast feeding or planning a pregnancy 2. presence of any skin condition that would interfere with the diagnosis or assessment of acne vulgaris (e.g., on the face: rosacea, dermatitis, psoriasis, squamous cell carcinoma, eczema, acneform eruptions caused by medications, steroid acne, steroid folliculitis, or bacterial folliculitis) 3. excessive facial hair (e.g., beards, sideburns, moustaches, etc.) that would interfere with diagnosis or assessment of acne vulgaris 4. history of hypersensitivity or allergy to adapalene, retinoids and/or any of the study medication ingredients 5. use within 6 months prior to baseline or during the study of oral retinoids (e.g., accutane®) or therapeutic vitamin a supplements of greater than 10,000 units/day (multivitamins are allowed) 6. use for less than 3 months prior to baseline of estrogens or oral contraceptives; use of such therapy must remain constant throughout the study 7. use on the face within 1 month prior to baseline or during the study of 1) cryo destruction or chemo destruction, 2) dermabrasion, 3) photodynamic therapy, 4) acne surgery, 5) intralesional steroids, or 6) x-ray therapy 8. use within 1 month prior to baseline or during the study of 1) systemic steroids, 2) systemic antibiotics, 3) systemic treatment for acne vulgaris (other than oral retinoids, which require a 6-month washout), or 4) systemic anti-inflammatory agents 9. use within 2 weeks prior to baseline or during the study of 1) topical steroids, 2) topical retinoids, 3) topical acne treatments including over-the-counter preparations, 4) topical anti-inflammatory agents, or 5) topical antibiotics
pre-operative characteristics for prediction of supraglottic airway failure using machine learning (erica)

Conditions: Anesthesia, General; Postoperative Complications; Laryngeal Masks; Treatment Failure

Summary: supraglottic airway devices (sga) are a safe and well-established technique for airway management. nowadays, up to 60% of general anaesthetics performed in european countries use sga. in 0.2-4.7% sga fail and require conversion to tracheal tubes. the erica study will use artificial intelligence methods to develop a model that can predict the risk of an unplanned sga conversion based on pre-operative characteristics available during the premedication visit.

an intraoperative change of procedure not only leads to time delays but also time delays, but also involves measures that are stressful for the patient, such as deepening the anaesthesia and manipulating the airway again. therefore, the objective of erica is to develop a machine learning algorithm based on preoperative information 1) that can accurately predict the risk of an unplanned sga conversion and 2) identifies characteristics leading to conversion from sga to tracheal tube. i. developing the model • the final dataset will be split in a training, testing, and validation cohort. five models will be created to predict intraoperative conversion from sga to tracheal tube including generalized linear models (glm), deep learning, distributed random forest (drf), xgboost and gradient boosting machine (gbm). then, a stacked ensemble model will be constructed through combination of the five models. finally, the best artificial intelligence model will be chosen. ii. identify characteristics leading to the airway conversion and categorisation. * intraoperative changes of the patient's position can alter the risk of conversion, therefore operations with positional changes should be considered * identify patient- and procedure-dependent characteristics that lead to conversion from sga to tracheal tube and their importance.

Eligibility criteria:
inclusion criteria: * adult patients (≥18 years) receiving general anaesthesia for non-cardiac surgery with a supraglottic airway device exclusion criteria: * none

Keywords: "neural networks, computer artificial intelligence"[mesh] "laryngeal masks"[mesh] "treatment failure"[mesh] "treatment outcome"[mesh] "risk factors"[mesh]
pilot study to evaluate optical frequency domain imaging for diagnosis of central airway disease

Conditions: Squamous Cell Lung Cancer; Lung Cancer

Summary: this study will evaluate a new imaging technology, termed optical frequency domain imaging (ofdi) for detecting and diagnosing pulmonary malignancy in the central airways.

the prevalence and high mortality rate associated with lung squamous cell carcinoma and the lack of any widely accepted screening and surveillance tools, highlights the need for new imaging paradigms that will ultimately lead to a reduction in patient mortality. bronchial carcinoma-in-situ will progress to invasive cancer in over 40% of individuals, and although the progression occurs over a long period of time, the majority of carcinomas are detected in the later stages of disease development, offering patients only a slim chance of cure. although significant effort in the development of screening paradigms for the detection of lung cancer in the central airways have been made, to date there is still no widely accepted and validated approach. optical frequency domain imaging (ofdi) is a recent derivative of optical coherence tomography (oct). ofdi can be used to conduct volumetric microscopy of the airways at a resolution comparable with architectural histopathology. the long term goal of this study is to use ofdi to screen the airways with the hope of detecting squamous cell carcinoma at an early more curable stage. standard of care bronchoscopy preparation and procedures will be followed including moderate sedation, pulse oximetry and blood pressure monitoring as per department protocol. a combination of currently approved bronchoscopy techniques including standard white light bronchoscopy, autofluorescence bronchoscopy, and narrow band imaging will be used to assess the airways. bronchial regions of interest (roi) suspected to be premalignant or malignant, will be imaged using the ofdi system and catheter prior to biopsy acquisition. it is anticipated that a minimum of 3 ofdi-biopsy correlated pairs from each study participant will be obtained. an additional ofdi and biopsy will be obtained from a normal roi. it is expected that the experimental procedure will add less than 10 minutes to the total length of the bronchoscopy procedure, but a stopping rule will be instituted to ensure that the experimental procedure does not exceed 20 minutes.

Eligibility criteria:
inclusion criteria: * patients undergoing bronchoscopy for known or suspected pulmonary malignancy in the central airways * patients must be over the age of 18 * patient must be able to give informed consent * women with child bearing potential must have a negative pregnancy test the day before or the day of the procedure. exclusion criteria: - patient does not meet the requirements to undergo clinical bronchoscopy, as determined by the treating physician.

Keywords: optical frequency domain imaging optical coherence tomography optical biopsy comprehensive microscopy
excimer light versus blue light in acne

Conditions: Acne Vulgaris

Summary: the aim is to assess the efficacy and safety of excimer light versus blue light in the treatment of inflammatory acne.

the use of new light energy in inflammatory acne

Eligibility criteria:
inclusion criteria: * patients with mild to moderate inflammatory acne lesions exclusion criteria: * pregnancy during the first trimester * female patients with a medical history of pco * topical and systemic treatment within the last month and systemic retinoids for 6 months * patients on systemic steroid treatment or hormonal therapy * severe systemic illness or malignancy * photosensitivity * scarring acne vulgaris